What is Prime Medicine's R&D?

Prime Medicine (PRME) reported R&D of $34.11M in Q1 2026.

How has Prime Medicine's R&D changed year-over-year?

Prime Medicine's R&D decreased by 15.9% year-over-year, from $40.56M to $34.11M.

What is the long-term trend for Prime Medicine's R&D?

Over 3 years (2022 to 2025), Prime Medicine's R&D has grown at a 22.8% compound annual growth rate (CAGR), from $86.73M to $160.64M.

Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.

Prime Medicine PRME R&D

R&D at other companies

Eli LillyLLY

$3.51B+28.4%

Intellia TherapeuticsNTLA

$80.74M-25.5%

CRISPR TherapeuticsCRSP

$68.57M-5.4%

Beam TherapeuticsBEAM

$104.52M+5.8%

RegenxbioRGNX

$57.34M+8.0%

Sana BiotechnologySANA

$28.72M-22.8%

Other financials

Income statement

See full

Revenue$838.0K-61.6%

Operating income-$50.7M+3.3%

Net income-$49.1M+5.3%

EPS (diluted)-$0.28+30.0%

Balance sheet

See full

Cash & equivalents$77.8M-26.6%

Total debt$114.5M-5.5%

Total equity$76.7M-28.3%

Total assets$294.7M-10.2%

Cash flow

See full

Operating cash flow-$42.7M+12.6%

CapEx$214.0K-91.2%

Free cash flow-$42.9M+16.3%

Valuation

See full

Market cap$574.36M+111%

Enterprise value$611.08M+113%

P/S124×+6.3×

Profitability

See full

Operating margin-4,498.1%-1,134pp

Net margin-4,342.4%-1,099pp

FCF margin-3,607.4%—

Returns & leverage

See full

Return on equity-216.1%+1,519pp

Debt / equity1.5×+0.4×

Current ratio3.8×-1.0×

Where this comes from

Reported directly by Prime Medicine in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Prime Medicine’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Prime Medicine's r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Prime Medicine's R&D?: Prime Medicine (PRME) reported R&D of $34.11M in Q1 2026.
How has Prime Medicine's R&D changed year-over-year?: Prime Medicine's R&D decreased by 15.9% year-over-year, from $40.56M to $34.11M.
What is the long-term trend for Prime Medicine's R&D?: Over 3 years (2022 to 2025), Prime Medicine's R&D has grown at a 22.8% compound annual growth rate (CAGR), from $86.73M to $160.64M.
What does R&D mean?: Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.